U.S. Markets close in 2 hrs 2 mins

Trevi Therapeutics, Inc. (TRVI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.8982-0.0518 (-5.45%)
As of 04:00PM EST. Market open.

Trevi Therapeutics, Inc.

195 Church Street
14th Floor
New Haven, CT 06510
United States
203 304 2499

Full Time Employees23

Key Executives

NameTitlePayExercisedYear Born
Ms. Jennifer L. GoodCo-Founder, CEO, Pres, Principal Financial Officer & Director662.64kN/A1965
Dr. Thomas R. SciasciaCo-Founder & Chief Medical Officer476.25kN/A1953
Mr. Christopher GallettaController & Chief Accounting OfficerN/AN/A1978
Dr. Amale HawiSr. VP of CMCN/AN/A1954
Mr. Frank P. MuscoloExec. OfficerN/AN/A1957
Dr. William P. Forbes Pharm.D., Pharm. D.Chief Devel. OfficerN/AN/A1962
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated with pruritus. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation; and Rutgers to develop and commercialize products incorporating nalbuphine for any human or animal use. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Corporate Governance

Trevi Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.